3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Conditions
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
49
fludarabine phosphate
42
fludarabine
37
Azacitidine
35
Busulfan
30
Whole-Body Irradiation
26
Imatinib Mesylate
24
Antilymphocyte Serum
24
Tacrolimus
23
Mycophenolic Acid
22
Cytarabine
21
Filgrastim
20
Peripheral Blood Stem Cell Transplantation
17
Methotrexate
17
Melphalan
17
Cyclosporine
16
venetoclax
14
thymoglobulin
14
Granulocyte Colony-Stimulating Factor
14
Thiotepa
12
ruxolitinib
11
Stem Cell Transplantation
11
Decitabine
11
Dasatinib
11
Alemtuzumab
11
nilotinib
10
Radiotherapy
10
Rituximab
9
Cord Blood Stem Cell Transplantation
9
ponatinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
angiotensin I (1-7)
×
Myeloid
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled